Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 83.5% in June

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 254,500 shares, an increase of 83.5% from the May 31st total of 138,700 shares. Based on an average trading volume of 839,200 shares, the days-to-cover ratio is presently 0.3 days.

Astellas Pharma Stock Performance

Shares of ALPMY stock opened at $9.86 on Friday. The company has a market capitalization of $17.84 billion, a P/E ratio of 140.86 and a beta of 0.39. Astellas Pharma has a fifty-two week low of $9.15 and a fifty-two week high of $15.90. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a 50 day moving average price of $9.76 and a two-hundred day moving average price of $10.65.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings data on Thursday, April 25th. The company reported $0.11 EPS for the quarter. Astellas Pharma had a net margin of 1.20% and a return on equity of 5.85%. The business had revenue of $2.79 billion during the quarter. Analysts expect that Astellas Pharma will post 0.36 earnings per share for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.